Tempus

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, PSNL, Neoplasm, Immunotherapy, Investment, DX, Lung, LDT, NeXT, Medicare, Tempus, MRD, Genomics, Partnership, Video game

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Infectious Diseases, Health, Medical Supplies, Medical Devices, Shift, COVID-19, SARS-CoV-2, Tempus

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

Key Points: 

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels
5.39 Tempus Announces COVID-19 Testing, Data Initiative
5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

Experienced Legal and Computer Engineering Expert Jennifer Davis Brings Important Perspectives to Scrum Alliance® Board of Directors

Retrieved on: 
Monday, February 26, 2024
Education, Training, Continuing, New York Law School, IBM, Growth, University, Medicine, Tempus, Teaching, Privacy, Management

Jennifer Davis offers a trio of unique experiences in her new role as a Scrum Alliance board member: she’s an accomplished lawyer who has worked with agile coaches and also holds a computer engineering degree.

Key Points: 
  • Jennifer Davis offers a trio of unique experiences in her new role as a Scrum Alliance board member: she’s an accomplished lawyer who has worked with agile coaches and also holds a computer engineering degree.
  • Davis is associate general counsel for Tempus, a precision medicine company, and previously served in roles at IBM and Spotify.
  • The Scrum Alliance Board of Directors has a minimum of nine members.
  • Of these, three are elected by Scrum Alliance members and referred to as Scrum Certified Member Directors.

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Retrieved on: 
Friday, January 5, 2024
Technology, Medical Devices, Health Technology, Software, Biotechnology, Internet, Health, Data Management, Oncology, Partnership, MRD, System, PSNL, Bank statement, Tempus, MVP, Genomics, Investment

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.
  • “To touch on a few highlights, over this past year we launched our NeXT Personal Dx ultrasensitive MRD product, deepened clinical evidence to support obtaining reimbursement, presented unprecedented clinical evidence for early-stage lung cancer detection at medical conferences, expanded our relationships with research collaborators, and forged a new strategic commercial partnership with Tempus to commercialize and ramp our MRD product, all while reducing our annualized expenses by $35 million.
  • I’m very proud of our progress and we expect to further leverage our clinical and commercial strength to drive more success in 2024.”
    The above information is preliminary and subject to Personalis’ normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm.
  • In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2023, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.

Biotech Veteran Marc Yoskowitz Named Evozyne CEO

Retrieved on: 
Thursday, January 4, 2024
Professional Services, Health, Technology, Finance, General Health, Artificial Intelligence, Biotechnology, Paragon, Pfizer, McKinsey & Company, Drug discovery, Protein, OrbiMed, Hospira, Tempus, Patient, NVIDIA

Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.

Key Points: 
  • Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
  • Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, corporate development and strategy expertise to the role.
  • Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity,” Yoskowitz said.
  • Founded in 2020 by Paragon Biosciences, Evozyne develops novel proteins that solve high-impact problems in human health.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Retrieved on: 
Monday, December 4, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Marketing, Medicare, NeXT, Genomics, Patient, PSNL, MRD, Pharmaceutical industry, Chief Justice of Hungary, Tempus

Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.

Key Points: 
  • Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.
  • By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually.
  • This action, along with the recently announced Tempus collaboration , is expected to extend the cash position of the company into 2026.
  • “Continuing to optimize our resources, as well as building new relationships, have been goals for us this year as we position Personalis to be a clinical testing leader,” stated Chris Hall, President and CEO of Personalis.

Cadence Signoff Solutions Empower Samsung Foundry’s Breakthrough Success on 5G Networking SoC Design

Retrieved on: 
Thursday, November 30, 2023
Technology, Mobile, Wireless, Semiconductor, 5G, Telecommunications, Software, Networks, Internet, Hardware, PPA, Head, Intelligent system, Samsung Electronics, SOC, Digital, CDNS, Cadence Design Systems, Tempus, Samsung, Kunyu Wanguo Quantu, Mobile phone, Sales, Cadence

Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced that Samsung Foundry successfully taped out a 5G networking SoC design on the Samsung 5LPE technology using the Cadence® Quantus™ Extraction Solution and Tempus™ Timing Solution.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced that Samsung Foundry successfully taped out a 5G networking SoC design on the Samsung 5LPE technology using the Cadence® Quantus™ Extraction Solution and Tempus™ Timing Solution.
  • This accomplishment marks a turning point for Samsung Foundry where the team deployed the Cadence signoff solutions for the first time, achieving a 2X productivity boost that led to faster design closure versus its previous design methodology.
  • The team also experienced significant power, performance and area (PPA) gains on this 120M instance design using the Cadence integrated flow.
  • The tools and flow support the company’s Intelligent System Design™ strategy, enabling customers to achieve SoC design excellence.

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Retrieved on: 
Tuesday, November 28, 2023
Oncology, Health, Technology, Genetics, Health Technology, Artificial Intelligence, Breast cancer, Genomics, Patient, Medicine, LDT, MRD, Intelligence, Marketing, NeXT, Lung cancer, Cancer, Recurrence, Immunotherapy, Neoplasm, PSNL, Medical imaging, Chief Justice of Hungary, Tempus

NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity.

Key Points: 
  • NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity.
  • The test was launched by Personalis in October of this year.
  • The two companies will work together exclusively in tumor-informed MRD testing for lung cancer, as well as breast cancer and immunotherapy monitoring after clinical validation of NeXT Personal Dx in those indications.
  • The agreement contemplates testing up to tens of thousands of new patients over the next three years.

Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies

Retrieved on: 
Wednesday, November 15, 2023
Oncology, Health, Technology, Health Technology, Genetics, Health Insurance, Artificial Intelligence, MSI, DNA, TMB, Patient, Medicine, Intelligence, Bone marrow, Medicare, NGS, Biomarker, Immunotherapy, Physician, Connective tissue, Medical imaging, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laboratory located in Research Triangle Park in North Carolina.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laboratory located in Research Triangle Park in North Carolina.
  • xT is now covered for Medicare patients under the MolDx program for tumor-only as well as normal match sequencing in all solid tumors, and tumor sequencing for patients with myeloid and suspected myeloid malignancies.
  • xT is covered for Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing (NGS) of tumor tissue to optimize treatment selection decisions.
  • “We’re pleased that Medicare is advancing coverage for biomarker testing for patients with both solid tumor and hematologic cancers,” said Eric Lefkofsky, Founder and CEO of Tempus.